JAK (Janus Kinase Pathway) Inhibitor Tofacitinib - pharmacology, mechanism of action, side effects

(3:7)

JAK inhibitors for IBD

(26:43)

Tofacitinib | JAK (Janus Kinase Pathway) Inhibitor Tofacitinib - pharmacology, mechanism of action.

(5:45)

When to use a JAK inhibitor in RA: Dr. Janet Pope

(5:7)

Mechanism of Action of JAK Inhibitors

(3:15)

How to talk to patients about JAK inhibitor safety | Victoria Ruffing

(6:42)

IBD Medications: JAK Inhibitors

(1:25)

What Are the Long-Term Effects of JAK Inhibitors?

(2:29)

Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias

(3:18)

JAK-Inhibition in Immune-Mediated Diseases (IMiDs)

(43:42)

ACR 2020 | Atul Deodhar discusses a phase 3 trial of tofacitinib in ankylosing spondylitis

(5:37)

New Therapies that Target the JAK-STAT Pathway and other Small Molecules

(16:48)

The role of JAK inhibitors in your clinical practice

(15:32)

A user's guide to JAK inhibition for IBD

(22:51)

Leveraging JAK Inhibitors in Ulcerative Colitis: Strategies for the IBD Management Team

(20:57)

JAK Inhibitors in Rheumatoid Arthritis

(26:3)

JAK Inhibitors - New FDA Approved Treatment!

(6:10)

Jak Inhibitors: Safety of Tofacitinib - Alexei Grom (on behalf of Hermine Brunner)

(30:13)

The Expanding Role of JAK Inhibitors Across IMIDs

(36:51)

JAK Inhibition: Are the Promises Fulfilled?

(53:32)